on the move but why?, page-2

CST has a great product with their Quantiferon Gold TB test.

It has been frustrating waiting for some sales although CST caused most the ongoing hiatus when they expedited the release of the Gold product which superseded the QF-1 product for which CST had gained FDA approval.

People following CST believe sales will come but find it difficult to forecast the timing of sales such as to the US military and Japan.

I have been impressed that CST has held the trading band around $1.40 and that Portfolio Partners have come on board.

The recent price action may be another flurry but today looks a lot more solid.